Methylxanthines [caffeine, pentoxifylline and theophylline] decrease the mutagenic effect of daunomycin, doxorubicin and mitoxantrone

• Autorzy: Piosik J. , Gwizdek-Wisniewska A. , Ulanowska K. , Ochocinski J. , Czyz A. , Wegrzyn G.
• Języki publikacji: EN

Abstrakty

EN

Previously performed experiments showed that methylxanthines, especially caffeine, may protect cells against cytostatic or cytotoxic effects of several aromatic compounds. One of the proposed mechanisms of this protection is based on stacking interactions between π electron systems of polycyclic aromatic molecules. In this work, we demonstrate that caffeine and other methylxanthines  -  pentoxifylline and theophylline - significantly decrease mutagenicity of the anticancer aromatic drugs daunomycin, doxorubicin and mitoxantrone. The spectrophotometric titration of these aromatic compounds by methylxanthines indicated formation of mixed aggregates. The concentrations of free active forms of the drugs decreased when the concentrations of methylxanthines increased in the mixture. Therefore, likely methylxanthines may play a role of scavengers of the free active forms of daunomycin, doxorubicin and mitoxantrone.

Słowa kluczowe

EN

caffeine; mutagenicity assay; daunomycin; xanthine; methylxanthine; chemical structure; Vibrio harveyi; pentoxifylline; mitoxantrone; theophylline

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2005
• Tom: 52
• Numer: 4
• Opis fizyczny: p.923-926,fig.,ref.

Twórcy

autor

Piosik J.

• University of Gdansk, Gdansk, Poland

autor

Gwizdek-Wisniewska A.

autor

Ulanowska K.

autor

Ochocinski J.

autor

Czyz A.

autor

Wegrzyn G.

Bibliografia

• Beetham KL, Busse PM, Tolmach LJ (1983) J Cell Physiol 115: 283–290.
• Bohm L, Theron T, Binder A (2000) Biochim Biophys Acta 1499: 1–10.
• Boike GM, Petru E, Sevin BU, Averette HE, Chou TC, Penalver M, Donato D, Schiano M, Hilsenbeck SG, Perras J (1990) Gynecol Oncol 38: 315–322.
• Chaires JB, Dattagupta N, Crothers DM (1982) Biochemistry 21: 3927–3932.
• Czyz A, Jasiecki J, Bogdan A, Szpilewska H, Wegrzyn G (2000) Appl Environ Microbiol 66: 599–605.
• Czyz A, Szpilewska H, Dutkiewicz R, Kowalska W, Biniewska- Godlewska A, Wegrzyn G (2002) Mutat Res 519: 67–74.
• Donovan PJ, Dipaolo JA (1974) Cancer Res 34: 2720–2727.
• Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ Jr, O’Connor PM (1995) Cancer Res 55: 1649–1654.
• Fingert HJ, Kindy RL, Pardee AB (1984) J Urol 132: 609– 613.
• Fingert HJ, Chang JD, Pardee AB (1986) Cancer Res 46: 2463–2467.
• Graham DM (1978) Nutr Rev 36: 97–102.
• Hande KR (1998) Biochim Biophys Acta 1400: 173–184.
• Heitmann C, Durmus C, Ingianni G (1998) J Hand Surg (Br) 3: 666–668.
• Johnson IM, Kumar SG, Malathi R (2003) J Biomol Struct Dyn 20: 677–686
• Kapuscinski J, Kimmel M (1993) Biophys Chem 35: 46–53.
• Kapuscinski J, Ardelt B, Piosik J, Zdunek M, Darzynkiewicz Z (2002) Biochem Pharmacol 63: 625–634.
• Kassner E (2000) J Pediatr Oncol Nurs 17: 135–148.
• Kharasch ED, Novak RF (1984) Arch Biochem Biophys 234: 497–512.
• Klein G, Walczak R, Krasnowska E, Blaszczak A, Lipinska B (1995) Mol Microbiol 16: 801–811.
• Labanowska J, Beetham KL, Tolmach LJ (1988) Radiat Res 115: 176–186.
• Marks V, Kelly JF (1973) Lancet 1: 827.
• Medvei KK, Sved S, Hossie RD, Garratini S (1974) Biomed Mass Spectrom 4: 172–177.
• Menozzi M, Valentini L, Vannini E, Arcamone F (1984) J Pharm Sci 73: 766–770.
• Mourelatos D, Dozi Vassiliades J, Kotsis A, Gourtsas C (1988) Cancer Res 48: 1129–1131.
• Nahon E, Best Belpomme M, Saucier JM (1993) Eur J Biochem 218: 95–102.
• Ohsaki Y, Ishida S, Fujikane T, Kikuchi K (1996) Oncology 53: 327–333.
• Petru E, Boike G, Sevin BU (1990) J Cancer Res Clin Oncol 116: 431–433.
• Piosik J, Zdunek M, Kapuscinski J (2002) Biochem Pharmacol 63: 635–646.
• Piosik J, Ulanowska K, Gwizdek-Wisniewska A, Czyz A, Kapuscinski J, Wegrzyn G (2003) Mutat Res 530: 47–57.
• Richardson DS, Johnson SA (1997) Blood Rev 11: 201–223.
• Roberts JJ (1984) In Mechanism of Potentiation by Caffeine of Genotoxic Damage Induced by Physical and Chemical Agents: Possible Relevance to Carcinogenesis. Dews PB, ed, pp 239–253. Springer-Verlag, Berlin, New York.
• Roberts JJ, Kotsaki Kovatsi VP (1986) Mutat Res 165: 207– 220.
• Rothwell K (1974) Nature 252: 69–70.
• Rudolph R, Larson DL (1987) J Clin Oncol 5: 1116–1126.
• Samlaska CP, Winfield EA (1994) J Am Acad Dermatol 30: 603–621.
• Selby CP, Sancar A (1990) Proc Natl Acad Sci USA 87: 3522–3525.
• Shannon M (2004) Clin Ped Emerg Med 1: 213–221.
• Slattery ML, Caan BJ, Anderson KE, Potter JD (1999) Int J Cancer 81: 199–204.
• Sparreboom A, de Jonge MJ, Verweij J (2002) Eur J Cancer 38: 18–22.
• Tanaka J, Teicher BA, Herman TS, Holden SA, Dezube B, Frei E (1991) Int J Cancer 48: 631–637.
• Tomita K, Tsuschiya H (1989) Jpn J Cancer Res 80: 83–88.
• Traganos F, Kaminska Eddy B, Darzynkiewicz Z (1991a) Cell Prolif 24: 305–319.
• Traganos F, Kapuscinski J, Darzynkiewicz Z (1991b) Cancer Res 51: 3682–3689.
• Traganos F, Kapuscinski J, Gong J, Ardelt B, Darzynkiewicz RJ, Darzynkiewicz Z (1993) Cancer Res 53: 4613–4618.
• Weller K, Schutz H, Petri I (1984) Biophys Chem 19: 289– 298.
• Williams JF, Lowitt S, Polson JB, Szentivany A (1978) Biochem Pharmacol 27: 1545–1550.
• Zdunek M, Piosik J, Kapuscinski J (2000) Biophys Chem 84: 77–85.